1. Search Result

Search Result

Targets Recommended: COMT PTEN SGK ATM/ATR SNIPER

Results for "And comt Inhibitors" in MCE Product Catalog:

14

Inhibitors & Agonists

3

Natural
Products

Cat. No. Product Name Target Research Areas
  • HY-106405
    Nebicapone

    BIA 3-202

    COMT Metabolic Disease
    Nebicapone (BIA 3-202), a reversible catechol-O-methyltransferase (COMT) inhibitor, is mainly metabolized by glucuronidation. Nebicapone is mainly peripherally acting inhibitor that decreases the biotransformation of L-DOPA to 3-O-methyl-DOPA by inhibition of COMT, and it is potential for the treatment of Parkinson's disease..
  • HY-14280A
    Entacapone sodium salt

    COMT Neurological Disease
    Entacapone sodium salt is a potent, reversible, peripherally acting and orally active catechol-O-methyltransferase (COMT) inhibitor. Entacapone sodium salt inhibits COMT from rat brain, erythrocytes and liver with IC50 values of 10 nM, 20 nM, and 160 nM, respectively. Entacapone sodium salt is selective for COMT over other catecholamine metabolizing enzymes, including MAO-A, MAO-B, phenolsulphotransferase M (PST-M) and PST-P (IC50s>50 µM). Entacapone sodium salt can be used for the research of Parkinson's disease. Entacapone sodium salt serves as a inhibits FTO demethylation activity with an IC50 of 3.5 μM and can be used for the research of metabolic disorders.
  • HY-14280
    Entacapone

    COMT Neurological Disease
    Entacapone is a potent, reversible, peripherally acting and orally active catechol-O-methyltransferase (COMT) inhibitor. Entacapone inhibits COMT from rat brain, erythrocytes and liver with IC50 values of 10 nM, 20 nM, and 160 nM, respectively. Entacapone is selective for COMT over other catecholamine metabolizing enzymes, including MAO-A, MAO-B, phenolsulphotransferase M (PST-M) and PST-P (IC50s>50 µM). Entacapone can be used for the research of Parkinson's disease. Entacapone serves as a inhibits FTO demethylation activity with an IC50 of 3.5 μM and can be used for the research of metabolic disorders.
  • HY-100562
    Flopropione

    5-HT Receptor COMT Neurological Disease
    Flopropione is a 5-HT receptor antagonist and also a catechol-o-methyltransferase (COMT) inhibitor. Flopropione also as an antispasmodic agent.
  • HY-B1473
    Serotonin hydrochloride

    5-Hydroxytryptamine hydrochloride; 5-HT hydrochloride

    5-HT Receptor COMT Endogenous Metabolite Neurological Disease
    Serotonin hydrochloride is a monoamine neurotransmitter in the CNS and an endogenous 5-HT receptor agonist. Serotonin hydrochloride is also a catechol O-methyltransferase (COMT) inhibitor with a Ki of 44 μM.
  • HY-14896
    Opicapone

    BIA 9-1067

    COMT Neurological Disease
    Opicapone is a potent third-generation catechol-O-methyltransferase (COMT) inhibitor for the research of Parkinson's disease and motor fluctuations. Opicapone decreases the ATP content of the cells with an IC50 of 98 μM.
  • HY-N0529
    Rosmarinic acid

    Labiatenic acid

    Monoamine Oxidase COMT Apoptosis Endogenous Metabolite Cancer
    Rosmarinic acid is a widespread phenolic ester compound in the plants. Rosmarinic acid inhibits MAO-A, MAO-B and COMT enzymes with IC50s of 50.1, 184.6 and 26.7 μM, respectively.
  • HY-113468A
    3-O-Methyldopa

    3-Methoxy-L-tyrosine; 3-O-Methyl-L-DOPA

    Dopamine Receptor Endogenous Metabolite Neurological Disease
    3-O-Methyldopa (3-Methoxy-L-tyrosine) is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of l-DOPA and dopamine.
  • HY-100642
    3-O-Methyltolcapone

    Ro 40-7591

    COMT Neurological Disease
    3-O-Methyltolcapone (Ro 40-7591) is a metabolite of Tolcapone. Tolcapone is an orally active, reversible, selective and potent COMT inhibitor. Tolcapone crosses the blood-brain barrier, and can be used for treatment of Parkinson's disease.
  • HY-106842
    Nitecapone

    OR-462

    COMT Inflammation/Immunology Neurological Disease
    Nitecapone (OR-462) is an orally active and short-acting catechol-O-methyltransferase (COMT) inhibitor with gastroprotective and antioxidant properties. Nitecapone (OR-462) scavenges reactive oxygen and nitric radicals and prevents lipid peroxidation.
  • HY-17406
    Tolcapone

    Ro 40-7592

    COMT Amyloid-β Neurological Disease
    Tolcapone (Ro 40-7592) is a selective, potent and orally active COMT inhibitor. Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis and protect against extracellular toxicity induced by the aggregation of both proteins in PC12 cells.
  • HY-17406S
    Tolcapone D7

    Ro 40-7592 D7

    COMT Amyloid-β Neurological Disease
    Tolcapone D7 (Ro 40-7592 D7) is a deuterium labeled Tolcapone. Tolcapone is a selective, potent and orally active COMT inhibitor. Tolcapone is also a potent inhibitor of α-syn and Aβ42 oligomerization and fibrillogenesis and protect against extracellular toxicity induced by the aggregation of both proteins in PC12 cells.
  • HY-113468AS
    3-O-Methyldopa D3

    3-Methoxy-L-tyrosine D3; 3-O-Methyl-L-DOPA D3

    Dopamine Receptor Endogenous Metabolite Neurological Disease
    3-O-Methyldopa D3 (3-Methoxy-L-tyrosine D3) is deuterium labeled 3-O-Methyldopa. 3-O-Methyldopa is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of l-DOPA and dopamine.
  • HY-100642S
    3-O-Methyltolcapone D7

    Ro 40-7591 D7

    COMT Neurological Disease
    3-O-Methyltolcapone D7 (Ro 40-7591 D7) is a deuterium labeled 3-O-Methyltolcapone. 3-O-Methyltolcapone is a metabolite of Tolcapone. Tolcapone is an orally active, reversible, selective and potent COMT inhibitor. Tolcapone crosses the blood-brain barrier, and can be used for treatment of Parkinson's disease.